TABLE 4.
Summary of Published Reports of c-kit Expression and Mutation in TEMs
| Reports | Samples | IHC − | IHC + | Mutation − | Mutation + | Described Mutations |
|---|---|---|---|---|---|---|
| Retrospective studies | ||||||
| Henley et al.12 | Thymoma | 19 | 1 (5%) | |||
| T. carcinoma | 4 | 11 (73%) | ||||
| Pan et al.36 | Thymoma | 110 | 0 | |||
| T. carcinoma | 3 | 19 (86%) | 21 | |||
| Nakagawa et al.13 | Thymoma | 48 | 2 (4%) | |||
| T. carcinoma | 4 | 16 (80%) | ||||
| Tsuchida et al.16 | Thymoma | 20 | 0 | |||
| T. carcinoma | 6 | 11 (65%) | 9 | |||
| Yoh et al.15 | Thymoma | 24 | 0 | 22 | ||
| T. carcinoma | 15 (88%) | 10 | 1 | L576P | ||
| Girard et al.14 | Thymoma | 33 | 0 | 38 | ||
| T. carcinoma | 3 | 3 (50%) | 5 | 2 | V560del | |
| Phase II studies | ||||||
| Salter et al.27 | T. carcinoma | 2 | 9 | |||
| Giaceone et al.20 | Thymoma | 2 | 0 | 2 | ||
| T. carcinoma | 1 | 1 | 1 | |||
| Case reports | ||||||
| Strobel et al.17 | T carcinoma | 1 | 1 | V560del | ||
| Bisagni et al.18 | T. carcinoma | 1 | 1 | D820E | ||
| Li et al37 | T. carcinoma | 1 | ||||
| Vasamiliette et al.28 | T. carcinoma | 1 | ||||
| Our series | Thymoma | 103 | 4 (4%) | 5 | ||
| T. carcinoma | 7 | 6 (46%) | 8 | |||
| Total | Thymoma | 359 | 7 (2%) | 67 | 0 | |
| Thymic carcinoma | 32 | 95 (75%) | 54 | 5 | ||
IHC, immunohistochemistry; TEM, thymic epithelial malignancy.